by Dr. William Chamberlin
On July 26, 2016, the United States Food and Drug Administration (FDA) issued a warning regarding the use of antibiotics in the fluoroquinolone class. These include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin and gemifloxacin (Factive).
Two of these drugs (levofloxacin and ciprofloxacin) are sometimes prescribed to treat Crohn’s disease via a pathogen model (AMAT). However, the risks associated with the fluoroquinolone class of medications are serious. Because of this, I will no longer recommend the use of levofloxacin or ciprofloxacin for the treatment of Crohn’s disease, except in extreme cases where the benefits may outweigh the serious risks.
Western culture tends to emphasize the importance of the individual more as an independent entity whereas Asian philosophy stresses the individual’s role as a component within a greater society. Both perspectives are valid; they are just different ways of conceptualizing what one is observing.
This short paper is offered in an attempt to illustrate that the dysbiosis theory and the infectious theory of Crohn’s disease are not mutually exclusive.
Immune Modulating Drug Stimulates Innate Immunity, Down-Regulates Unproductive Inflammation and Promotes Th1 Immunity
People have asked for more information on Formulated EpiBro (FepiBro).
A formulation of 16-bromoepiandrosterone (Epi-Br) was originally developed and investigated under the name HE2000. There is extensive literature on its activity against infectious diseases. It underwent human trials as an immune modulating drug designed to combat the major infectious diseases in the “Developing World.” The HE2000 formula demonstrated activity against HIV/AIDS, malaria and tuberculosis in nine human trials. It was shown to be safe and effective.
Read on to see why it wasn’t further developed and why it could now help Crohn’s disease patients.
A team out of New Zealand has discovered Ziehl-Neelsen positive bacteria in blood cells of dendritic cell and macrophage lineage. The importance of finding a Ziehl-Neelsen positive unidentified bacterial species inside circulating macrophages is under investigation. Logic suggests that therapies that enhance innate immunity, regulate immune signaling and control ineffective inflammation will restore immune efficacy so that a patient’s immune system can effectively handle a chronic intracellular microbial disease. Formulated EpiBro (or FepiBro) possesses the above qualities.